

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

| APPLICATION NO.                            | FILING DATE    | FIRST NAMED INVENTOR | ATTORNEY DOCKET NO.     | CONFIRMATION NO |
|--|----------------|----------------------|-------------------------|-----------------|
| 09/891,823                                 | 06/26/2001     | John R. Neefe        | 12071-003001            | 2643            |
| 7.   | 590 08/13/2002 |                      |                         |                 |
| LEE CREWS, PH. D.                          |                |                      | EXAMINER                |                 |
| Fish & Richardson P.C. 225 Franklin Street |                |                      | SALIMI, ALI REZA        |                 |
| Boston, MA 02110-2804                      |                |                      | ART UNIT                | PAPER NUMBER    |
|  |                |                      | 1648                    | Ca              |
| ١  |                |                      | DATE MAILED: 08/13/2002 | . 8             |

Please find below and/or attached an Office communication concerning this application or proceeding.

# Office Action Summary

Application No. 09/891,823

Applicant(s)

Neefe et al

Examiner

A. R. SALMI

Art Unit **1648** 



|  | The MAILING DATE of this communication appears   | on the cover sheet with the correspondence address   |  |  |  |
|--|--|--|--|--|--|
| Period f   | for Reply  |  |  |  |  |
| THE N  | ORTENED STATUTORY PERIOD FOR REPLY IS SET MAILING DATE OF THIS COMMUNICATION. ions of time may be available under the provisions of 37 CFR 1.136 (e). In date of this communication. | TO EXPIRE One MONTH(S) FROM  no event, however, may a reply be timely filed after SIX (6) MONTHS from the                            |  |  |  |
| - If the p<br>- If NO p<br>- Failure<br>- Any re   | period for reply specified above is less than thirty (30) days, a reply within the   | and will expire SIX (6) MONTHS from the mailing date of this communication.<br>ne application to become ABANDONED (35 U.S.C. § 133). |  |  |  |
| Status   |  | •  |  |  |  |
| 1) 💢   | Responsive to communication(s) filed on 4/22/02,   | 1/30/02  |  |  |  |
| 2a) 🗌  | This action is <b>FINAL</b> . 2b) ☐ This act   | ion is non-final.  |  |  |  |
| 3) 🗆   | Since this application is in condition for allowance $\epsilon$ closed in accordance with the practice under $Ex$ pa   | except for formal matters, prosecution as to the merits is rte Quayle, 1935 C.D. 11; 453 O.G. 213.                                   |  |  |  |
| Disposit   | tion of Claims   |  |  |  |  |
| 4) 💢   | Claim(s) <u>1-35</u>   | is/are pending in the application.   |  |  |  |
| 4  | a) Of the above, claim(s)  | is/are withdrawn from consideration.   |  |  |  |
| 5) 🗆   | Claim(s)   | is/are allowed.  |  |  |  |
| 6) 🗆   | Claim(s)   | is/are rejected.   |  |  |  |
| 7) 🗆   | Claim(s)   | is/are objected to.  |  |  |  |
| 8) 💢   | Claims <u>1-35</u>   | are subject to restriction and/or election requirement.  |  |  |  |
|  | tion Papers  |  |  |  |  |
| 9) 🗆   | The specification is objected to by the Examiner.  | •  |  |  |  |
| 10)  | The drawing(s) filed on is/are   | a) accepted or b) objected to by the Examiner.   |  |  |  |
|  | Applicant may not request that any objection to the d  | rawing(s) be held in abeyance. See 37 CFR 1.85(a).   |  |  |  |
| 11)  | The proposed drawing correction filed on   | is: a) $\square$ approved b) $\square$ disapproved by the Examiner.  |  |  |  |
|  | If approved, corrected drawings are required in reply t  | to this Office action.   |  |  |  |
| 12)  | The oath or declaration is objected to by the Exami  | ner.   |  |  |  |
| Priority   | under 35 U.S.C. §§ 119 and 120   |  |  |  |  |
| 13) Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). |  |  |  |  |  |
| a) 🗆   | ] All b)□ Some* c)□ None of:   |  |  |  |  |
| 1  | I. $\square$ Certified copies of the priority documents hav  | e been received.   |  |  |  |
| 2  | $2.\square$ Certified copies of the priority documents have  | e been received in Application No  |  |  |  |
| 3  | 3. Copies of the certified copies of the priority do application from the International Burea  | ocuments have been received in this National Stage au (PCT Rule 17.2(a)).  |  |  |  |
| *Se  | ee the attached detailed Office action for a list of the   |  |  |  |  |
| 14)  | Acknowledgement is made of a claim for domestic  | priority under 35 U.S.C. § 119(e).   |  |  |  |
| a) 🗆   | The translation of the foreign language provisiona   | I application has been received.   |  |  |  |
| 15) 🗌  | Acknowledgement is made of a claim for domestic  | priority under 35 U.S.C. §§ 120 and/or 121.  |  |  |  |
| Attachme   | • •  | _  |  |  |  |
| _  | ice of References Cited (PTO-892)  | 4) Interview Summary (PTO-413) Paper No(s).  |  |  |  |
|  | ice of Draftsperson's Patent Drawing Review (PTO-948)  | 5) Notice of Informal Patent Application (PTO-152)   |  |  |  |
| 3) Information Disclosure Statement(s) (PTO-1449) Paper No(s) 6) X Other: SEQUENCE LETTER        |  |  |  |  |  |

Art Unit: 1648

## **DETAILED ACTION**

The Art Unit location of your application in the USPTO has changed. To aid in correlating any papers for this application, all further correspondence regarding this application should be directed to Art Unit 1648.

## Sequence Requirements

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures. For example, See TABLE 4.

Full compliance with the sequence rules is required in response to this Office Action. A complete response to this office action should include both compliance with the sequence rules and a response to the election/restriction requirement set forth below. Failure to fully comply with **both** these requirements in the time period set forth in this office action will be held non-responsive.

Application/Control Number: 09/891,823 Page 3

Art Unit: 1648

## Election/Restriction

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- Claims 1-13, drawn to a method of treating wart, classified in class 424, subclass 204.1.
- II. Claims 14-29, 34, drawn to method of treating a condition associated with human papillomavirus, classified in class 435, subclass 5.
- III. Claims 30-31, drawn to a method of treating wart by administering nucleic acid, classified in class 435, subclass 320.1.
- IV Claims 32-33, 35, drawn to treating a condition associated with papillomavirus by viral vector, classified in class 424, subclass 199.1.

The inventions are distinct, each from the other because of the following reasons:

Inventions of Groups I-IV are directed to mutually exclusive and patentably distinct methods each are functionally and substantially different. The examination of all groups would require different searches in the U.S. Patent Shoes, in house and commercial databases, and scientific literature and would require the consideration of different patentability issues.

Art Unit: 1648

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, restriction for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(I).

#### Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to A. R. Salimi whose telephone number is (703) 305-7136. The examiner can normally be reached on Monday-Friday from 9:00 Am to 6:00 Pm.

Art Unit: 1648

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James Housel, can be reached on (703) 308-4027. The fax phone number for this Group is (703) 305-3014, or (703) 308-4242.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308-0196.

A. R. Salimi

8/6/2002

ALL P. SALIMINER PRIMARY EXAMINER